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Abstract
Aims/hypothesis Obesity is the dominant cause of insulin
resistance. In adult humans it is characterised by a combina-
tion of adipocyte hypertrophy and, to a lesser extent, adipocyte
hyperplasia. As hypertrophic adipocytes secrete more leptin
and less adiponectin, the plasma leptin:adiponectin ratio
(LAR) has been proposed as a potentially useful measure of
insulin resistance and vascular risk. We sought to assess the
usefulness of the LAR as a measure of insulin resistance in
non-diabetic white adults.
Methods Leptin and adiponectin levels weremeasured in 2,097
non-diabetic individuals from the Ely and European Group for
the Study of Insulin Resistance (EGIR) Relationship between
Insulin Sensitivity and Cardiovascular Risk (RISC) study
cohorts. LAR was compared with fasting insulin and HOMA-
derived insulin sensitivity (HOMA-S) in all individuals andwith
the insulin sensitivity index (M/I) from hyperinsulinaemic–
euglycaemic clamp studies in 1,226 EGIR RISC participants.
Results The LAR was highly correlated with HOMA-S in
men (r=−0.58, p=4.5×10−33 and r=−0.65, p=1.1×10−66
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within the Ely and EGIR RISC study cohorts, respectively)
and in women (r=−0.51, p=2.8×10−36 and r=−0.61, p=
2.5×10−73). The LAR was also strongly correlated with the
clamp M/I value (r=−0.52, p=4.5×10−38 and r=−0.47, p=
6.6×10−40 in men and women, respectively), similar to
correlations between HOMA-S and the M/I value.
Conclusions/interpretation The leptin:adiponectin ratio is a
useful measure of insulin resistance in non-diabetic white
adults. These data highlight the central role of adipocyte
dysfunction in the pathogenesis of insulin resistance. Given
that variations between fasting and postprandial leptin and
adiponectin levels tend to be small, the leptin to adiponectin
ratio might also have potential value in assessing insulin
sensitivity in the non-fasted state.
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Abbreviations
EGIR European Group for the Study of Insulin
Resistance
HOMA-S HOMA-derived insulin sensitivity
LAR Leptin:adiponectin ratio
RISC Relationship between Insulin Sensitivity and
Cardiovascular Risk
Introduction
Obesity-induced insulin resistance is a major aetiological factor
in the pathogenesis of type 2 diabetes mellitus. We hypoth-
esised that the ratio of plasma leptin to adiponectin (LAR)
might be a useful measure of insulin sensitivity, given: (1) the
central role of excess adipose tissue in insulin resistance; (2)
the now well-recognised capacity of adipose tissue to produce
hormones (adipocytokines) involved in the regulation of
energy balance and insulin action; and (3) the fact that the
two best characterised adipocytokines (leptin and adiponectin)
respond in a reciprocal manner to increasing adiposity [1]. The
ratio has previously been shown to correlate with carotid
intimal medial thickness [2] and to predict the presence of the
metabolic syndrome [3]. However, its correlation with insulin
sensitivity has not previously been established.
Methods
Leptin and adiponectin were measured in stored fasting
serum samples of 2,097 individuals from two large
epidemiological cohorts, using previously described assays
[4, 5]. All individuals had HOMA-derived insulin sensitivity
(HOMA-S) estimated using an online calculator (www.dtu.
ox.ac.uk/homa) [6]. In addition, 1,226 individuals in the
European Group for the Study of Insulin Resistance (EGIR)
Relationship between Insulin Sensitivity and Cardiovascular
Risk (RISC) study had insulin sensitivity measured using the
hyperinsulinaemic–euglycaemic clamp technique. Insulin
sensitivity was expressed as the ratio of the mean glucose
infusion rate (M, adjusted for fat-free mass) to the mean
plasma insulin (I) over the final 40 min of the clamp (M/I).
Medical Research Council Ely Cohort The study design,
methods and measurements for this predominantly Europid-
population-based cohort study in Ely, Cambridgeshire, UK
have been described previously [7]. Briefly, individuals were
recruited between 1990 and 1992, using a sampling frame of
all non-diabetic adults living in Cambridgeshire. Participants
attended the testing site after an overnight fast, and had
blood samples drawn once. Written informed consent was
obtained. Approval for the study was obtained from the
Cambridge Local Research Ethics Committee.
EGIR RISC study cohort This prospective, observational
cohort study involved participants from 19 centres across
Europe, as described previously [8]. Healthy men and women
aged between 30 and 60 years were included. Exclusion
criteria were hypertension, dyslipidaemia, prevalent diabetes,
pregnancy, treatment for obesity, known cardiovascular or
chronic lung disease, weight change of 5 kg in the preceding
6 months, cancer within the previous 5 years or renal failure.
However, unlike the Ely cohort, individuals with incident
diabetes diagnosed at the time of their study visit were
included in the current analysis. Local ethics committee
approval was obtained by each recruiting centre, and all
participants provided written informed consent. During the
hyperinsulinaemic–euglycaemic clamp, exogenous insulin was
administered as a primed-continuous intravenous infusion at a
rate of 240 pmol min−1m−2 simultaneously with a variable
20% (wt/vol.) glucose infusion. This was adjusted every 5 to
10 min to maintain plasma glucose levels within 0.8 mmol/l of
the target glucose level (4.5–5.5 mmol/l). The M/I value for
insulin sensitivity was calculated from the integral of the
glucose infusion rate during the final 40 min of glucose
infusion, divided by the steady-state insulin concentration.
Descriptive statistics are presented as means with 95%
confidence intervals. Non-normally distributed data were
log transformed prior to analysis, using the natural log (e).
In order to compare the LAR with other standard indices of
insulin resistance (fasting insulin and HOMA-S), linear
regression models were used to separately derive stand-
ardised beta coefficients (β±standard error) between log
LAR, log HOMA-S and log fasting insulin (as predictors)
and log M/I (as outcome). Correlations between these
measures were calculated using Pearson’s correlation.
Analyses were stratified by study cohort and by sex,
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because there were significant interactions for the LAR
with sex and with study cohort.
Results
Participant characteristics are outlined in Table 1. Overall,
12.7% of study participants were obese (Electronic supple-
mentary material [ESM] Table 1). Leptin, adiponectin and
the LAR were higher in women than in men. There were
strong and statistically significant correlations between
LAR and fasting insulin and HOMA-S in both sexes and
both cohorts, as summarised in Table 2. When analysed
separately, correlations with fasting adiponectin and leptin
levels were consistently less good than those achieved with
the LAR (data not shown). In linear regression modelling,
the overall association between log LAR and log M/I was
similar to the association between log 1/HOMA-S and log
M/I (β=−0.49±0.025 and −0.48±0.025, respectively;
p=0.68), and was also similar to the association between
log fasting insulin and log M/I (β=−0.49±0.025; p=0.86).
In subgroup analyses of lean, overweight and obese male
and female participants separately, the strengths of the
associations between LAR and other measures of insulin
sensitivity retained statistical significance and remained
similar (ESM Table 2).
Table 1 Baseline characteristics of participants in the Ely and EGIR RISC studies
Baseline characteristics Ely study EGIR RISC study
Men Women Men Women
n 356 515 534 692
Age (years) 54.3 (53.4–55.1) 53.3 (52.6–53.9) 43.2 (42.5–43.9) 44.4 (43.8–45.1)
BMI (kg m−2) 25.9 (25.6–26.2) 25.6 (25.2–26.0) 26.4 (26.1–26.6) 24.8 (24.4–25.1)
Fasting insulin (pmol/l)a 39.0 (36.9–41.2) 38.2 (36.5–40.0) 32.9 (31.4–34.4) 29.2 (28.1–30.4)
Fasting triacylglycerols (mmol/l)a 1.35 (1.28–1.42) 1.11 (1.06–1.16) 1.12 (1.08–1.17) 0.85 (0.82–0.88)
Fasting glucose (mmol/l) 5.82 (5.77–5.87) 5.60 (5.56–5.65) 5.22 (5.17–5.26) 4.94 (4.90–4.99)
HOMA-Sa 131.9 (124.7–139.4) 135.9 (129.7–142.4) 160.5 (153.5–167.8) 183.1 (176.1–190.5)
Leptin (ng/ml)a 3.69 (3.35–4.07) 13.84 (12.88–14.86) 4.01 (3.64–4.40) 14.62 (13.75–15.54)
Adiponectin (µg/ml)a 5.23 (4.99–5.47) 8.22 (7.90–8.55) 6.07 (5.88–6.26) 9.24 (8.97–9.50)
LARa (ng/µg)a 0.71 (0.63–0.79) 1.68 (1.54–1.84) 0.66 (0.60–0.73) 1.58 (1.47–1.70)
Clamp M/I (μmol min−1kg FFM−1nmol−1)a 110.8 (106.4–115.4) 140.6 (135.9–145.4)
Values are arithmetic mean (95% CI)
a Geometric mean
FFM, fat-free mass
Table 2 Correlations between measures of insulin resistance in participants from the Ely and EGIR RISC studies
Men Women
r (95% CI) p value r (95% CI) p value
Ely study
Correlations with log LAR
Log fasting insulin 0.57 (0.50, 0.64) 1.9×10−32 0.51 (0.45, 0.57) 7.5×10-36
Log HOMA-S −0.58 (−0.64, −0.50) 4.5×10−33 −0.51 (−0.58, −0.45) 2.8×10−36
EGIR RISC study
Correlations with log LAR
Log fasting insulin 0.66 (0.60–0.70) 4.5×10−67 0.62 (0.57, 0.66) 1.5×10−73
Log HOMA-S −0.65 (−0.70, −0.60) 1.1×10−66 −0.61 (−0.66, −0.57) 2.5×10−73
Correlations with log M/I
Log fasting insulin −0.52 (−0.58, −0.46) 1.4×10−38 −0.46 (−0.52, −0.40) 1.8×10−37
Log HOMA-S 0.51 (0.45–0.57) 2.5×10−37 0.45 (0.39, 0.51) 5.9×10−36
Log LAR −0.52 (−0.58,−0.45) 4.5×10−38 −0.47 (−0.53, −0.41) 6.6×10−40
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Discussion
Leptin and adiponectin differ from almost all other adipocy-
tokines in being secreted exclusively by adipocytes. Although
details of all the factors regulating their synthesis, secretion
and clearance remain incomplete, plasma leptin levels
increase proportionally with fat mass, whereas adiponectin
levels decrease with weight gain. Accumulating data suggest
that the capacity of adipose tissue to accommodate ongoing
energy excess is finite [9], and that ‘overloaded’ adipocytes
ultimately undergo necrosis or apoptosis, precipitating an
inflammatory response which may contribute to the devel-
opment of insulin resistance [10]. Given the central role of
obesity in the pathogenesis of insulin resistance, we
hypothesised that the ratio of plasma leptin and adipo-
nectin levels would reflect compromised adipose tissue
function and provide a useful index of insulin action.
Our analysis of this ratio in two large, population-based
samples strongly supports this hypothesis. Furthermore, our
analyses confirm that the LAR is at least as strongly
associated with the gold standard measure of insulin
resistance (clamp M/I value) as currently used methods such
as fasting insulin or HOMA-S. Given the size of the
populations studied, and the statistical significance of the
associations, these findings are robust.
Further studies are required in younger people and in those
with diabetes to determine the validity of the LAR as ameasure
of insulin resistance in these groups. However, emerging data
in young people suggest that leptin and adiponectin are good
markers of insulin resistance [11]. Use of the LAR as a marker
of insulin resistance in diabetic individuals requires further
clarification, as previous observations involved skewed data
from relatively small numbers of patients [12], though it has
been shown to reflect atherosclerotic change in diabetic
individuals [2]. Also, rare exceptions exist where insulin
resistance is associated with high adiponectin concentrations
and where the ratio would clearly not be valid [13].
Additionally our data pertain to two predominantly white
populations, in whom adiponectin levels tend to be higher
than in other ethnic groups [14] and so further validation
studies are required in these groups. Last, the relative expense
of leptin and adiponectin assays compared with cheaper
glucose and insulin assays might limit their utility.
Notwithstanding these limitations, this study affirms the
central role of excess adiposity in modulating insulin action,
and offers a potentially useful tool for quantifying insulin
resistance on a large scale. Moreover, given that circadian
and postprandial variations in leptin and adiponectin levels
are modest [15], the LAR has potential additional value as a
measure of insulin resistance because, in contrast to
conventional indices of insulin action, it may be a valid
measure of insulin resistance even when measured in the
non-fasted state. Leptin and adiponectin are also very stable
in plasma or serum whereas insulin is not (data not shown).
Clearly this is an area that requires further investigation, as
our analysis included only participants who had samples
taken while fasting. However, removing the need for fasting
samples would significantly increase the efficiency and
feasibility of insulin resistance measurements in large
population-based studies.
Acknowledgements The RISC Study is partly supported by EU
grant QLG1-CT-2001-01252. Additional support for the RISC Study
has been provided by AstraZeneca (Sweden). The EGIR Group is
supported by Merck Santé (France). F. M. Finucane, J. Luan, N. J.
Wareham and S. J. Sharp are funded by the Medical Research
Council. D. B. Savage is supported by a Clinical Fellowship from
GlaxoSmithKline and by the UK NIHR Cambridge Biomedical
Research Centre.
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Badman MK, Flier JS (2007) The adipocyte as an active participant
in energy balance andmetabolism. Gastroenterology 132:2103–2115
2. Satoh N, Naruse M, Usui T et al (2004) Leptin-to-adiponectin
ratio as a potential atherogenic index in obese type 2 diabetic
patients. Diabetes Care 27:2488–2490
3. Zhuo Q, Wang Z, Fu P et al (2009) Comparison of adiponectin,
leptin and leptin to adiponectin ratio as diagnostic marker for
metabolic syndrome in older adults of Chinese major cities.
Diabetes Res Clin Pract 84:27–33
4. Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A (2005)
Increased serum adiponectin levels in type 1 diabetic patients with
microvascular complications. Diabetologia 48:1911–1918
5. Semple RK, Soos MA, Luan J et al (2006) Elevated plasma
adiponectin in humans with genetically defective insulin receptors. J
Clin Endocrinol Metab 91:3219–3223
6. Wallace TM, Matthews DR (2002) The assessment of insulin
resistance in man. Diabet Med 19:527–534
7. Williams DR, Wareham NJ, Brown DC et al (1995) Undiagnosed
glucose intolerance in the community: the Isle of Ely Diabetes
Project. Diabet Med 12:30–35
8. Hills SA, Balkau B, Coppack SW et al (2004) The EGIR-RISC
STUDY (The European Group for the Study of Insulin Resistance:
Relationship between Insulin Sensitivity and Cardiovascular Disease
Risk): I. Methodology and objectives. Diabetologia 47:566–570
9. Gray SL, Vidal-Puig AJ (2007) Adipose tissue expandability in
the maintenance of metabolic homeostasis. Nutr Rev 65:S7–12
10. Cinti S, Mitchell G, Barbatelli G et al (2005) Adipocyte death
defines macrophage localization and function in adipose tissue of
obese mice and humans. J Lipid Res 46:2347–2355
11. Hung YJ, Chu NF, Wang SC et al (2006) Correlation of plasma
leptin and adiponectin with insulin sensitivity and beta-cell
function in children—the Taipei Children Heart Study. Int J Clin
Pract 60:1582–1587
2348 Diabetologia (2009) 52:2345–2349
12. Oda N, Imamura S, Fujita T et al (2008) The ratio of leptin to
adiponectin can be used as an index of insulin resistance. Metab
Clin Exper 57:268–273
13. Semple RK, Halberg NH, Burling K et al (2007) Paradoxical
elevation of high-molecular weight adiponectin in acquired
extreme insulin resistance due to insulin receptor antibodies.
Diabetes 56:1712–1717
14. Considine RV, Premkumar A, Reynolds JC, Sebring NG, Ricks
M, Sumner AE (2008) Adiponectin and leptin in African
Americans. Obesity (Silver Spring) 16:428–434
15. Gavrila A, Peng CK, Chan JL, Mietus JE, Goldberger AL, Mantzoros
CS (2003) Diurnal and ultradian dynamics of serum adiponectin in
healthymen: comparisonwith leptin, circulating soluble leptin receptor,
and cortisol patterns. J Clin Endocrinol Metabol 88:2838–2843
Diabetologia (2009) 52:2345–2349 2349
